- Belgrade '18
- Vienna '18
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
Session Title: New IOLs
Session Date/Time: Tuesday 08/10/2013 | 16:30-18:15
Paper Time: 17:29
Venue: Elicium 1 (First Floor)
First Author: : F.Auerbach GERMANY
Co Author(s): : A. Fitting R. Khoramnia T. Rabsilber G. Auffarth M. Holzer
Clinical evaluation of functional results and quality of vision after implantation of an aspheric, aberration free, monofocal intraocular lens (IOL).
International Vision Correction Research Centre (IVCRC), Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany
So far, 10 eyes of 8 patients (median age: 63.5 years) with cataract have been enrolled in this ongoing prospective clinical study that was approved by the ethics committee. The MicroCryl MC 6125 AS aspheric IOL (HumanOptics/Dr.Schmidt Intraocularlinsen, Germany) was implanted after phacoemulsification. Follow-up examinations were performed one to four months after surgery including subjective refraction, ETDRS uncorrected (UDVA) and corrected distance visual acuity (CDVA), wavefront analysis, analysis of stray light (C-Quant), contrast sensitivity under different lighting conditions (F.A.C.T.) and a questionnaire.
One to four months after surgery, median UDVA was 0.10 logMAR (range: -0.06 to 0.76 logMAR). Median CDVA increased from 0.21 logMAR (range: 0.00 to 0.70 logMAR) preoperatively to -0.12 logMAR (range: -0.16 to 0.06 logMAR) postoperatively. Median difference between achieved vs. intended spherical equivalent was +0.29 D (range: -0.57 to +0.76 D). Median total HOA RMS (6 mm pupil size) was 1.98 µm (range: 1.14 to 4.81 µm). The median spherical aberrations were -0.47 µm (range: -0.73 to -0.36 µm). Analysis of stray light (C-Quant) revealed a median value of 1.27 log(s) (range: 1.10 to 1.55 log(s)).
The MicroCryl aspheric IOL provides good and predictable functional results after surgery. Patients are not negatively influenced by stray light and show slightly negative spherical aberrations.
... gains financially from competing product or procedure, ... travel has been funded, fully or partially, by a competing company, ... research is funded, fully or partially, by a competing company
Please wait while information is loading.